



Maine Immunization Program- Preparing For COVID-19 Vaccination



Objectives

- ACIP Recommendations for Phase 1a
- Planned Phases
- Distribution of COVID-19 Vaccine
- Vaccines Offered with Storage and Handling Requirements
 - Pfizer
 - Moderna
- Ancillary Supply Kit
- Emergency Use Authorization (EUA) Fact Sheets
- Resources
- Q&A

Advisory Committee of Immunization Practice (ACIP) Recommendations

- Advisory Committee of Immunization Practice (ACIP) approved the following recommendation by majority (13-1) vote at its December 1, 2020 emergency meeting.
 - When a COVID-19 vaccine is authorized by FDA and recommended by ACIP, vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a) should be offered to both 1) health care personnel[§] and 2) residents of long-term care facilities[¶]
 - [§]Health care personnel are defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials
 - [¶] Long-term care facility residents are defined as adults who reside in facilities that provide a variety of services, including medical and personal care, to persons who are unable to live independently
- The ACIP recommendation has been adopted by the U.S. CDC Director

<https://www.cdc.gov/vaccines/acip/recommendations.html>

Planned Phases for COVID-19 Vaccination

Phase 1

Phase 1a “Jumpstart Phase”:

- High-risk workers in health care facilities
- First responders

Phase 1b:

- People of all ages with comorbid and underlying conditions that put them at significantly higher risk
- Older adults living in congregate or overcrowded settings

Phase 2

- Critical risk workers—workers who are both in industries essential to the functioning of society and at substantially high risk of exposure
- Teachers and school staff
- People of all ages with comorbid and underlying conditions that put them at moderately higher risk
- All older adults not included in Phase 1
- People in homeless shelters or group homes for individuals with physical or mental disabilities or in recovery
- People in prisons, jails, detention centers, and similar facilities, and staff who work in such settings

Phase 3

- Young adults
- Children
- Workers in industries essential to the functioning of society and at increased risk of exposure not included in Phase 1 or 2

Phase 4

- Everyone residing in the United States who did not receive the vaccine in previous phases

<http://nap.edu/25914>, [Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine](#), 9/2/2020

Distribution of COVID-19 Vaccine

- Maine has been allocated 12,675 doses of the Pfizer COVID-19 vaccine product for phase 1a
 - Dose 2 will not be included in the first shipment
- Hospitals and Pharmacies will be the first to receive phase 1a shipments of COVID-19 vaccine
 - Vaccine will be shipped within 24 hours of placing an order
- All orders for the COVID-19 vaccine must be placed in Immpact
 - Interested sites must complete a COVID-19 Provider Agreement with the Maine Immunization Program in order to gain access to ordering COVID-19 vaccine
 - Visit [ImmunizeME.org](https://immunizeme.org), COVID-19 Vaccine Providers Portal for further details

Pfizer COVID-19 Vaccine

- Storage conditions for multi-dose vial
 1. -60 to -80 F Ultra-cold (-28 to -48 C)
 - » Up to 6 months from manufactures expiration date
 2. -58 to 5 F (-50 to 15 C) regular freezer storage
 - » Up to 5 days
 3. 36 – 46 F (2-8 C) regular fridge storage
 - » 48hours only
- Thawing
 - 3hrs at 36-46 F (2-8 C) or 30min at room temperature
- Post-dilution
 - Must be administered with in 6 hours
- 2 dose series given Intramuscular (IM) Injection
 - .3ml drawn up
 - given 21 days apart
- Not interchangeable
 - Same vaccine must be given for both doses

Pfizer- Thermal Shipping Container

- Attached data logger with GPS included with the shipper
 - Data logger will confirm if temp is stable with a green (with in range) or red (out of range) light
- Includes supplies for re-icing thermal shipping container
 - Protective equipment provided with shipment
 - gloves, goggles and dry ice for 1 re-icing are included
- Thermal shipping container holds temperature for 10days
 - Re-icing must take place every 5days
- Thermal shipper must be returned w/in 10 businesses days, no later than 20 business days.
 - Replace components and seal shipper for return

Moderna COVID-19 Vaccine

- Storage conditions for a multi-dose non-punctured vial
 - Freezer: -13-5 F / -25 to -15 C for 6months
 - Refrigerator: 36-46 F / 2-8 C for up to 30 days. Do not refreeze
 - Room temperature: up to 12 hours
- Discard any punctured vial after 6 hours
- No diluent required
- 2 dose series given Intramuscular (IM) Injection
 - .5ml drawn up
 - Given 28 days apart
- Not interchangeable
 - Same vaccine must be given for both doses

Moderna COVID-19 Vaccine Shipping

- Undetermined allotment of Moderna vaccine for Maine
- Must be a COVID-19 vaccine provider to place order in Immpact system with the Maine Immunization Program
- Ships with in 24 hours of placing an order
- Do not store in shipping box
- Moderna COVID-19 vaccine must be placed in freezer storage unit upon receiving shipment of the vaccine

Ancillary Supply Kit

Ancillary supplies will be packaged in kits and will be automatically ordered in amounts to match vaccine orders

- A. Each kit will contain supplies to administer 100 doses of vaccine, including:
 - Needles, 105 per kit (various sizes for the population served by the ordering vaccination provider)
 - 25-gauge, 1" (if vaccination indicated for pediatric population)
 - 22–25-gauge, 1-1.5" (adult)
 - Syringes, 105 per kit (ranging from 1–3 mL)
 - Alcohol prep pads, 210 per kit
 - 4 surgical masks and 2 face shields for vaccinators per kit
 - COVID-19 vaccination record cards for vaccine recipients, 100 per kit
 - Vaccine needle guide detailing the appropriate length/gauge for injections based on route, age (for children), gender, and weight (for adults)
- A mixing kit will be included if a COVID-19 vaccine requires diluent for reconstitution of the vaccine.
 - Gloves are not required unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. If worn, perform hand hygiene and change gloves between patients.
- Ancillary supply kits will not include sharps containers, gloves, and bandages. Additional personal protective equipment (PPE) may be needed depending on vaccination provider site needs.

COVID-19 Vaccine Emergency Use Authorization (EUA) Fact Sheets

- Product-specific EUA fact sheet for COVID-19 vaccination providers will be made available and include
 - information on the specific vaccine product
 - instructions for its use.
- An EUA fact sheet for vaccine recipients will also be developed, and both will likely be made available on the FDA website and through the CDC website.
- Required to provide the recipient fact sheet to each client/patient prior to administering vaccine.

Resources

- ImmunizeME.org- Maine Immunization Website
 - [COVID-19 Interim Draft Vaccination Plan](#)
- COVID-19 Vaccination
 - <https://www.cdc.gov/vaccines/covid-19/>
- Vaccines
 - <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/>
- Frequently Asked Questions About COVID-19 Vaccination
 - <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html>
- Maine Immunization Program Website
 - [ImmunizeME.org](https://immunizeME.org)
- Vaccine Manufacture Website
 - www.Pfizer.com
 - www.modernatx.com

Questions?

Amanda Luciano
Project Coordinator/Vaccine Educator
Amanda.Luciano@maine.gov
207-287-9930
www.ImmunizeME.org

